Agronomics (ANIC) invests in cellular agriculture companies. This note provides an update on our January 2022 initiation note, following the release of ANIC’s interim results and the announcement of several new and follow-on portfolio investments. Two of these investments have resulted in uplifts to the valuation of ANIC’s initial investments, which will add to the steady rise in its NAV since inception, as will ‘further significant developments’ in a number of portfolio holdings, foreshadowed in the latest interim report. Recent share price weakness, driven by broad market developments unrelated to ANIC’s portfolio holdings, has seen its substantial premium to NAV narrow sharply. However, several factors should provide underlying support for the share price, including the company’s conservative valuation policy, its scarcity value as the only UK-listed investment vehicle targeting cellular agriculture and this industry’s very favourable outlook. This suggests ANIC’s current relatively low share price and narrow premium provide investors with the opportunity to gain exposure to this growing, game-changing sector at an attractive level.
22 Mar 2022
Agronomics - Bright outlook for top investor in revolutionary sector
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Agronomics - Bright outlook for top investor in revolutionary sector
Agronomics Limited (ANIC:LON) | 7.9 0 1.3% | Mkt Cap: 79.7m
- Published:
22 Mar 2022 -
Author:
Joanne Collins -
Pages:
8
Agronomics (ANIC) invests in cellular agriculture companies. This note provides an update on our January 2022 initiation note, following the release of ANIC’s interim results and the announcement of several new and follow-on portfolio investments. Two of these investments have resulted in uplifts to the valuation of ANIC’s initial investments, which will add to the steady rise in its NAV since inception, as will ‘further significant developments’ in a number of portfolio holdings, foreshadowed in the latest interim report. Recent share price weakness, driven by broad market developments unrelated to ANIC’s portfolio holdings, has seen its substantial premium to NAV narrow sharply. However, several factors should provide underlying support for the share price, including the company’s conservative valuation policy, its scarcity value as the only UK-listed investment vehicle targeting cellular agriculture and this industry’s very favourable outlook. This suggests ANIC’s current relatively low share price and narrow premium provide investors with the opportunity to gain exposure to this growing, game-changing sector at an attractive level.